Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens
耐药和新发病原体组合药物方案设计实验室
基本信息
- 批准号:10596722
- 负责人:
- 金额:$ 514.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-16 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAddressAffectAnimalsAntimicrobial ResistanceBackBacteriaBacterial InfectionsBiomedical ResearchBostonCOVID-19 pandemicCenters for Disease Control and Prevention (U.S.)ClinicalClinical DataCollaborationsCombined Modality TherapyCommunicable DiseasesCountryDevelopmentDrug CombinationsEducationEmergency SituationEmerging Communicable DiseasesEngineeringEnvironmentEquipmentFacultyFeedbackGeneticGlossaryGoalsHIV/TBHealthHealth SciencesHospitalsHumanIncidenceIndustrializationIndustryInfectionInsectaInstitutionKnowledgeLaboratoriesLibrariesLinkMeasuresMedical centerMedicineModernizationMulti-Drug ResistanceMycosesNational SecurityNew EnglandParasitic infectionPathogenicityPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPoliciesPopulation HeterogeneityPublic HealthReadinessRegimenResearchResearch PersonnelResistanceResourcesSchoolsScientistSecuritySystemTechnologyTherapeuticTrainingTreatment ProtocolsUniversitiesVeterinary MedicineVeterinary SchoolsViralVirus DiseasesVisitWorkantimicrobialantimicrobial drugbench to bedsideclinical practicecombatcombinatorialdesigndrug efficacyemerging pathogenglobal healthimprovedinnovationinterestmembermulti-drug resistant pathogennovelnovel therapeuticspandemic diseasepathogenpathogenic bacteriapathogenic microbepathogenic viruspersonalized medicineresearch facilityresponsesquare foot
项目摘要
(a) Overview
The past two years have shown that infectious diseases are global threats, revealing an urgent need to improve
preparedness to combat unknown pathogens. Furthermore, the alarming increase in infections caused by
antimicrobial resistant (AMR; see glossary, below) pathogens in recent years, exacerbated by the COVID-19
pandemic, illustrates that we are also on the verge of losing our ability to treat infections caused by known
pathogens. Combination drug treatment is the therapeutic mainstay in the treatment of infections caused by
several microbial pathogens, including HIV and the tuberculosis bacterium. Still, systematic and efficient
development of such treatments for AMR or emerging pathogens is lacking. Tufts University (TU) is proposing
to construct a new biomedical research facility, the Laboratory for Combinatorial Drug Regimen Design for
Resistant and Emerging Pathogens (LCDRD), to design and develop new combinatorial therapeutic approaches
for bacterial, viral, fungal, and parasitic infections and to accelerate research on AMR and emerging pandemic
pathogens. The LCDRD is designed to facilitate the development of novel treatments for difficult-to-treat
infections due to pathogens from both animals and humans. In addition to generating new therapies for AMR or
emerging pathogens, this facility will provide diverse, well-characterized human bacterial pathogens with linked
clinical data from across ‘Tufts-Medicine’, a state-wide network of hospitals serving diverse populations, for study
by academia and industry. The Stuart B. Levy Tufts Center for Integrative Management of Antimicrobial
Resistance (CIMAR) unites faculty from TU and Tufts Medical Center (TMC), as well as affiliate members from
across the region and nation, with expertise in biomedical research, engineering, human and veterinary
medicine, global health, environmental surveillance, policy, and education, to catalyze the development of new
combinatorial drug strategies to treat a wide range of pathogens. Working with CIMAR in LCDRD will be the
nascent Center for Emerging Infectious Diseases and Response (CEIDAR), which addresses emerging and
expanding infectious disease threats such as insect-borne bacterial and viral pathogens. CEIDAR includes the
Tufts Lyme Initiative and utilizes the BSL-3 level Tufts New England Regional Biosafety Laboratory (NERBL) at
Tufts Cummings School of Veterinary Medicine in Grafton, an important resource for expanding work. Institutions
affiliated with CIMAR/CEIDAR span a spectrum of academic and pharmaceutical interests and, although located
locally at TU, will enhance transdisciplinary interactions among regional and national investigators and entities.
Project Goals: The LCDRD will enable specialized and collaborative work on emerging and resistant microbial
pathogens that is required to generate new combinatorial treatments. The facility will: 1) enhance interaction
between clinicians and biomedical researchers to generate therapeutic antimicrobial drug regimens, particularly
combination therapies, against CDCs urgent and emerging threat pathogens; 2) develop genetic and systems
approaches to facilitate ‘personalized medicine’ for patients with difficult-to-treat infection; 3) provide a space
where visiting scientists can receive hands-on training, allowing knowledge dissemination intra-institutionally,
regionally, nationally, and globally; and 4) increase the national capacity to respond to infectious disease
emergencies by providing academic and industrial entities access to libraries of well-characterized isolates for
emerging pandemic and AMR pathogens.
Affected Space and Requested Equipment: The LCDRD will provide a modern, centralized laboratory and
collaboration capacity for a multi-institutional effort to utilize state-of-the-art research technologies to generate
and characterize novel drug therapies for pathogens resistant to current therapeutic regimens as well as new
pandemic threats. It will provide a specialized and biosecure environment for researchers to work with multi-
drug resistant (MDR) and emerging pathogens. It will be built in an existing 2,400 sq. ft. shell space in the
Biomedical Research and Public Health Building on the Tufts Health Sciences campus in Boston. The new
facility, directly adjacent to Tufts’ existing BSL-3 lab and the laboratories of the PI and a key CIMAR investigator,
will be shared by teams of interdisciplinary researchers from four TU schools and TMC, as well as collaborators
from other regional and national institutions.
Impact on Research and Clinical Practice: The National Health Security Strategy, 2019-2022, states that “the
growing incidence of AMR has both public health and national security consequences” and that “expanding the
antimicrobial arsenal is a real and immediate requirement to avoid an era of untreatable infectious diseases.”
Through centralizing and leveraging our expertise in bacterial, viral, and MDR pathogens, innovative measures
of combinatorial drug efficacy, and deep clinical expertise in treatment-resistant infections, the LCDRD will
support the nation’s AMR crisis response by generating novel therapies, both at Tufts and in collaboration with
other academic and pharmaceutical entities across the country (Fig. 1). LCDRD will be a national center of
excellence that makes broadly available well-characterized pathogens with clinical data, allowing for linkage of
patient outcomes to strain-level pathogenicity and combination therapy. This will enable a true link from bedside
to bench and back—a feedback loop that will maintain a tight translational focus, inform treatment regimens for
current and emerging threats, and promote personalized medicine.
(a)概述
过去两年的情况表明,传染病是全球性的威胁,这表明迫切需要改进
做好应对未知病原体的准备。此外,由于艾滋病毒/艾滋病引起的感染令人震惊地增加,
近年来,新型冠状病毒肺炎(COVID-19)加剧了抗生素耐药(AMR;见下文术语表)病原体
大流行病,表明我们也即将失去治疗由已知疾病引起的感染的能力。
病原体联合药物治疗是治疗由感染引起的感染的主要治疗方法。
几种微生物病原体,包括艾滋病毒和结核菌。尽管如此,系统和高效
缺乏对AMR或新出现的病原体的这种治疗的开发。塔夫茨大学(Tufts University)
建设一个新的生物医学研究设施,实验室组合药物方案设计,
耐药和新兴病原体(LCDRD),设计和开发新的组合治疗方法
用于细菌、病毒、真菌和寄生虫感染,并加速对AMR和新出现的大流行病的研究
病原体LCDRD旨在促进难治性疾病的新型治疗方法的开发
来自动物和人类的病原体引起的感染。除了产生新的AMR疗法或
新出现的病原体,该设施将提供不同的,特征良好的人类细菌病原体与相关的
来自“塔夫茨医学”的临床数据,这是一个服务于不同人群的全州医院网络,用于研究
学术界和工业界。斯图尔特B。利维塔夫茨抗菌药物综合管理中心
阻力(CIMAR)联合来自TU和塔夫茨医学中心(TMC)的教师,以及来自
在整个地区和国家,在生物医学研究,工程,人类和兽医的专业知识,
医学、全球卫生、环境监测、政策和教育,以促进新的
治疗多种病原体的组合药物策略。在LCDRD中与CIMAR合作将是
新生的新发传染病和应对中心(CEIDAR),该中心负责处理新发和
不断扩大的传染病威胁,如昆虫传播的细菌和病毒病原体。CEIDAR包括
塔夫茨莱姆倡议,并利用BSL-3级塔夫茨新英格兰地区生物安全实验室(NERBL),
塔夫茨卡明斯兽医学院在格拉夫顿,扩大工作的重要资源。机构
隶属于CIMAR/CEIDAR跨越学术和制药利益的范围,虽然位于
在TU本地,将加强区域和国家研究人员和实体之间的跨学科互动。
项目目标:LCDRD将使新兴和耐药微生物的专业化和协作工作成为可能。
这些病原体是产生新的组合治疗所需的。该设施将:1)加强互动
临床医生和生物医学研究人员之间的合作,以产生治疗性抗微生物药物方案,特别是
联合疗法,针对CDC紧急和新兴威胁病原体; 2)开发遗传和系统
为难以治疗的感染患者提供“个性化医疗”的方法; 3)提供空间
访问科学家可以在那里接受实践培训,从而在机构内传播知识,
在区域、国家和全球范围内; 4)提高国家应对传染病的能力
紧急情况下,通过提供学术和工业实体访问图书馆的良好特征的分离物,
新出现的大流行和AMR病原体。
受影响的空间和要求的设备:LCDRD将提供一个现代化的集中实验室,
多机构合作能力,利用最先进的研究技术,
并描述对当前治疗方案耐药的病原体的新型药物疗法以及新的
流行病威胁。它将为研究人员提供一个专门的生物安全环境,
耐药(MDR)和新出现的病原体。它将建在现有的2,400平方米。英尺壳层空间
生物医学研究和公共卫生大楼在塔夫茨健康科学校园在波士顿。新
设施,直接毗邻塔夫茨现有的BSL-3实验室和PI的实验室和一个关键的CIMAR研究员,
将由来自四所TU学校和TMC的跨学科研究人员团队以及合作者共享
其他区域和国家机构。
对研究和临床实践的影响:2019 - 2022年国家健康安全战略指出,"
越来越多的AMR发生率具有公共卫生和国家安全后果","扩大
抗菌药物库是避免出现无法治愈的传染病时代的一个真实的迫切需要。"
通过集中和利用我们在细菌、病毒和MDR病原体方面的专业知识,
联合药物疗效和在耐药感染方面的深厚临床专业知识,LCDRD将
通过在塔夫茨大学并与合作开发新型疗法来支持国家的耐药性危机应对
全国其他学术和制药实体(图1)。LCDRD将成为一个国家中心,
卓越,使广泛可用的良好表征的病原体与临床数据,允许链接,
菌株水平致病性和联合治疗的患者结局。这将使真正的链接从床边
一个反馈回路,将保持一个紧密的翻译重点,告知治疗方案,
当前和新出现的威胁,并促进个性化医疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linden T Hu其他文献
Case 24-2015
案例24-2015
- DOI:
- 发表时间:
2015 - 期刊:
- 影响因子:0
- 作者:
Linden T Hu;Athe M. N. Tsibris;John A. Branda - 通讯作者:
John A. Branda
Linden T Hu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linden T Hu', 18)}}的其他基金
Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome
自身抗体作为治疗后莱姆病综合征的预测标记
- 批准号:
10737996 - 财政年份:2023
- 资助金额:
$ 514.71万 - 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
- 批准号:
10461854 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10397615 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
- 批准号:
10680556 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10606624 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10165497 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Role of human innate immune mutations in loss of tolerance to Borrelia burgdorferi
人类先天免疫突变在伯氏疏螺旋体耐受性丧失中的作用
- 批准号:
10256713 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
新型水库靶向伯氏疏螺旋体抗生素的开发和现场测试
- 批准号:
10674121 - 财政年份:2020
- 资助金额:
$ 514.71万 - 项目类别:
Understanding Human Immunological Responses to Ixodes Tick Bites
了解人类对硬蜱叮咬的免疫反应
- 批准号:
9807836 - 财政年份:2019
- 资助金额:
$ 514.71万 - 项目类别:
Coping with Stress: Next Generation Approaches to Borrelia burgdorferi Host Adaptation
应对压力:伯氏疏螺旋体宿主适应的下一代方法
- 批准号:
9892949 - 财政年份:2017
- 资助金额:
$ 514.71万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 514.71万 - 项目类别:
Research Grant














{{item.name}}会员




